These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19556699)

  • 1. Eicosapentaenoic acid (EPA) in reducing secondary cardiovascular events in hypercholesterolemic Japanese patients.
    Kohro T; Yamazaki T
    Circ J; 2009 Jul; 73(7):1197-8. PubMed ID: 19556699
    [No Abstract]   [Full Text] [Related]  

  • 2. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
    Matsuzaki M; Yokoyama M; Saito Y; Origasa H; Ishikawa Y; Oikawa S; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K; Matsuzawa Y;
    Circ J; 2009 Jul; 73(7):1283-90. PubMed ID: 19423946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia　- An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
    Kodera S; Morita H; Kiyosue A; Ando J; Komuro I
    Circ J; 2018 Mar; 82(4):1076-1082. PubMed ID: 29367520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
    Singh S; Arora RR; Singh M; Khosla S
    Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes.
    Bittner VA; Jacobson TA; Ballantyne CM; Guyton JR
    J Clin Lipidol; 2020; 14(1):4-15. PubMed ID: 32192643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects.
    Goyens PL; Mensink RP
    Eur J Clin Nutr; 2006 Aug; 60(8):978-84. PubMed ID: 16482073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eicosapentaenoic acid for prevention of major coronary events.
    Colhoun HM
    Lancet; 2007 Jul; 370(9583):215. PubMed ID: 17658384
    [No Abstract]   [Full Text] [Related]  

  • 9. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).
    Oikawa S; Yokoyama M; Origasa H; Matsuzaki M; Matsuzawa Y; Saito Y; Ishikawa Y; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K;
    Atherosclerosis; 2009 Oct; 206(2):535-9. PubMed ID: 19447387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. n-3 fatty acids and cardiovascular events after myocardial infarction.
    Kromhout D; Giltay EJ; Geleijnse JM;
    N Engl J Med; 2010 Nov; 363(21):2015-26. PubMed ID: 20929341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
    Saito Y; Yokoyama M; Origasa H; Matsuzaki M; Matsuzawa Y; Ishikawa Y; Oikawa S; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K;
    Atherosclerosis; 2008 Sep; 200(1):135-40. PubMed ID: 18667204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Nelson JR; True WS; Le V; Mason RP
    Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of omega-3 fatty acid supplementation in primary and secondary prevention of coronary heart disease.
    Weisman D; Motro M; Schwammenthal E; Fisman EZ; Tenenbaum A; Tanne D; Adler Y
    Isr Med Assoc J; 2004 Apr; 6(4):227-32. PubMed ID: 15115262
    [No Abstract]   [Full Text] [Related]  

  • 14. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
    Weintraub H
    Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
    Yokoyama M; Origasa H; Matsuzaki M; Matsuzawa Y; Saito Y; Ishikawa Y; Oikawa S; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K;
    Lancet; 2007 Mar; 369(9567):1090-8. PubMed ID: 17398308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and epidemiological study of eicosapentaenoic acid (EPA) in Japan.
    Tamura Y; Hirai A; Terano T; Saitoh H; Yoshida S
    J Nutr Sci Vitaminol (Tokyo); 1992; Spec No():140-3. PubMed ID: 1297726
    [No Abstract]   [Full Text] [Related]  

  • 18. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
    Bays HE; Tighe AP; Sadovsky R; Davidson MH
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).
    Sasaki J; Yokoyama M; Matsuzaki M; Saito Y; Origasa H; Ishikawa Y; Oikawa S; Itakura H; Hishida H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K; Matsuzawa Y;
    J Atheroscler Thromb; 2012; 19(2):194-204. PubMed ID: 22186099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
    Nakamura H;
    Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.